ERBB3 and neoplasm: Since c-Src inhibitor-1 (a selective dual site Src tyrosine kinase inhibitor of c-Src and Lck) was able to affect HER3 phosphorylation, they demonstrated that the combination of cetuximab with c-Src inhibitor-1 led to a concurrent decrease of EGFR and HER3 phosphorylation, significantly reducing tumor cell growth [92].